Viking Therapeutics Gains Momentum as Rival Stumbles

Viking Therapeutics shares surged after Novo Nordisk's CagriSema failed to match Eli Lilly's Tirzepatide in a key trial, easing competitive pressure on Viking's obesity drug candidate VK2735.

Monday brought a significant shift in the competitive landscape for weight-loss medications, with Viking Therapeutics emerging as a clear beneficiary. Investor sentiment turned following disappointing Phase 3 trial results from Novo Nordisk, which were seen as reducing competitive pressure on smaller biotech firms like Viking. The company's shares opened higher and advanced as much as 11% during the session.

A Competitive Setback for a Market Leader

The catalyst originated from Novo Nordisk, which announced that its drug candidate CagriSema failed to demonstrate non-inferiority against Eli Lilly's Tirzepatide in the Phase 3 REDEFINE 4 study. This open-label trial, involving 809 patients over 84 weeks, showed a mean weight loss of 23.0% for CagriSema, compared to 25.5% for Tirzepatide. Even after adjusting for treatment adherence, a gap remained, with results of 20.2% versus 23.6%, respectively.

This clinical shortfall placed substantial pressure on Novo Nordisk. According to Reuters data, its stock declined approximately 15%, falling to its lowest level since 2021.

Interpreting the Market Reaction for Viking

Viking Therapeutics is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity, targeting the same biological pathways as the leading competing drugs. The market's response is logical: when a dominant competitor shows weaker efficacy in a head-to-head comparison, the competitive environment appears less daunting for clinical-stage challengers. This perception holds provided Viking's own program delivers compelling data in upcoming trial phases.

Trading data from MarketBeat showed Viking's stock opened at $32.60 on Monday, up from a prior close of $31.03. The share price reached an intraday level of $34.22, with reported volume around 1.89 million shares.

Operational Progress and Financial Standing

In a business update on February 11, Viking highlighted several key operational milestones. Patient recruitment for the Phase 3 VANQUISH-1 trial, evaluating subcutaneous VK2735 in approximately 4,500 participants, concluded ahead of schedule. The VANQUISH-2 trial, focusing on obesity with type 2 diabetes in about 1,100 patients, is nearing full enrollment.

Furthermore, guided by positive FDA feedback from an End-of-Phase 2 meeting, an oral formulation of VK2735 is slated to enter Phase 3 development in the third quarter of 2026. A separate maintenance study investigating various dosing regimens is fully recruited, with data expected also in Q3 2026. The company previously indicated plans to submit an Investigational New Drug (IND) application for a novel amylin agonist in the first quarter of 2026.

Financially, the picture is well-defined. For the full year 2025, Viking reported a net loss of approximately $359.6 million, or a loss per share (EPS) of -$3.19. Its fourth-quarter EPS was -$1.38, missing the consensus estimate of -$0.89. However, the company's cash position remains robust, with $706 million in cash and equivalents reported at the end of the quarter.

Regarding the broader market context, Novo Nordisk has already submitted CagriSema to the FDA based on earlier REDEFINE studies, with a regulatory decision anticipated by the end of 2026. Viking's foundational data comes from a prior Phase 2 study (VENTURE), which demonstrated weight reduction of up to 14.7% after 13 weeks of subcutaneous treatment. The firm's next critical tests will be the upcoming Phase 3 data readouts and other scheduled milestones in 2026, including those in the third quarter.